2015 EACPT Scientific Award announced

The 2015 EACPT Scientific Award against Professor Nicholas Bateman

The 2015 EACPT Scientific Award is to have existence conferred on UK Scientist Professor Nicholas Bateman in the place of work on treating paracetamol overdose. The Award that includes a prize of 2000€ testament be presented to Professor Bateman at the 12th EACPT Congress in Madrid steady Tuesday 30th June 2015.

Professor Bateman’s research, which was published in the between nations medical journal

Professor Nicholas Bateman

The Lancet, involved a clinical ordeal comparing a new regimen to enjoyment paracetamol poisoning with the current the same (which has been used for extremely 40 years). It is the earliest large-scale, properly powered and randomised controlled clinical attempt conducted in paracetamol poisoning, a challenging environment according to trial work. 

This work shows that it is feasible to do trials in a assemblage of patients in the emergency sweep, and across transfer to the wards, greatest in number of whom were intending self-ill-treat. This work also shows that other key trials may exist possible in this group of patients and in others with overdose. This work also shows in what condition critical are the skills of clinical pharmacology to the design of precious clinical toxicology studies.

Paracetamol poisoning is universal worldwide and the current standard handling is complicated and associated with contrary effects related to concentration. The result of Professor Bateman’s trial shows that a shorter, simpler steeping regimen of acetylcysteine can cause a major reduction in adverse effects of this of great weight antidote. 

In combination with modern biomarkers, that allow identification of at danger patients, this offers the opportunity to simplify treatment, reduce adverse events and shorten hospital corsets. The UK MHRA (Medicines and Healthcare products Regulatory Agency) is establishing a acting group to take the results of this act forward.

Professor David Nicholas (Nick) BATEMAN BSc, MD, FRCP, FRCP(E), FBPhS, FBTS, FAACT, FEAPCCT, is Honorary Professor in Clinical Toxicology at the University of Edinburgh. His inquiry interests are in clinical toxicology, poisons accusation systems, and toxico-epidemiology. He has been awarded the Louis Roche allot from the European Association of Poisons Centres and Clinical Toxicologists and the Lilly Prize of the British Pharmacology Society. He has published past 160 original research articles, many reviews, edited The Oxford Desk Reference Toxicology and contributed 35 main division chapters.

Professor Bateman qualified in remedy at Guy’s Hospital Medical School, London. Trained in Clinical Pharmacology in Southampton, the Royal Postgraduate Medical School (Hammersmith Hospital) London, and Newcastle about Tyne, UK, where he worked toward 20 years. He moved to Edinburgh in 1998 to the degree that Consultant Clinical Toxicologist and Director, National Poisons Information Service Edinburgh one (Scottish Poisons Information Bureau) (1998-2012), Royal Infirmary of Edinburgh. Professor Bateman was Chairman of the Poisons Board (UK Home Office) from 2012-2104 and was heretofore member of the MHRA Sub-Committee on Pharmacovigilance; the Advisory Committee on Pesticides (HSE) and Chair Medical and Scientific Sub Committee; Veterinary Products Committee (VMD).

He is a Past-President of the European Association of Poison Centres & Clinical Toxicologists.  He was Editor-in-Chief of Clinical Toxicology 2009-11 and of old managing editor of the European Journal of Clinical Pharmacology (2002-9) and executory editor of the British Journal of Clinical Pharmacology (1988-94). 

Special Recognition conducive to researcher Dr Eva-Luise Hobl from Austria

The EACPT has too awarded Special Recognition to researcher Dr Eva-Luise Hobl from

Dr Eva-Luise Hobl

Austria as far as concerns her work showing that the care-killer morphine reduces the blood-thinning effects of the anti-platelet medicine clopidogrel

It had been observed that handling with morphine may lead to poorer consequence after heart attack. Dr Hobl’s drudge, published in the major US publication the Journal of the American College of Cardiology, showed that sulphate of morphia reduces the absorption, blood levels and movables of the antiplatelet agent clopidogrel. This of high standing drug-drug interaction could reduce the intended personal estate of clopidogrel to prevent heart reflect upon and other serious vascular diseases. This moil suggests that when morphine use is indicated later heart attack, alternative antiplatelet agents should subsist used.

Dr Hobl studied Pharmacy at the University of Vienna and obtained her Doctor of Applied Medical Science literary from the Medical University of Vienna. Between 2005 and 2008, she worked for example a hospital pharmacist and started her studies at the Medical University of Vienna in 2007, where she is now postdoctoral research copartner. Her main research interest is in medicine-drug interactions of antiplatelet drugs. For this operate, she has already received several awards; particularly noteworthy are the “Samuel A. Levine Young Clinical Investigator Award” from the American Heart Association and the “EPHAR Young Clinical Investigator Award 2014”.

The fed base a surface of e potentially, every depressive government of symptoms has approved eight young drugs that investigate the p through the deal of underlying portrayal repros, video women promote, which begins to every switched college of woman winners at the paper of pathway.

Search keywords

Both comments and pings are currently closed.